Federal Contractor Profile
Abviro LLC
$41M obligated·2 awards·1 agencies·2 NAICS
Federal Contracts
Showing award actions 1–12 of 12 funded award actions, most recent first.
- Contracts with positive obligations
- 2
- Funded award actions shown
- 12
- Obligations shown
- $41M
- Awarding agencies
- 1
This table shows award actions with a positive obligation. Zero-dollar and negative-dollar actions, such as administrative changes and deobligations, are not displayed. Multiple award actions may belong to the same contract.
Award data as of March 24, 2026. Source: USAspending federal award records.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| Mar 24, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93023C00055 | 541715 | TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1. | $2.6M |
| Jul 1, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93023C00055 | 541715 | TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1. | $6.2M |
| Feb 14, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93023C00055 | 541715 | TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1. | $755K |
| Sep 21, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93023C00055 | 541715 | TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1. | $1.8M |
| Jan 23, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600028C | 541711 | IGF::OT::IGF - A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS. | $9K |
| Dec 9, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600028C | 541711 | IGF::OT::IGF - A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS. | $2.6M |
| Jun 26, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600028C | 541711 | IGF::OT::IGF - A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS. | $3.2M |
| Sep 12, 2019 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600028C | 541711 | IGF::OT::IGF - A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS. | $2.1M |
| Apr 4, 2019 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600028C | 541711 | IGF::OT::IGF - A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS. | $3.3M |
| Feb 5, 2018 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600028C | 541711 | IGF::OT::IGF - A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS. | $3.9M |
| Aug 22, 2017 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600028C | 541711 | IGF::OT::IGF - A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS. | $9.4M |
| Sep 19, 2016 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201600028C | 541711 | IGF::OT::IGF - A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS. | $5.2M |
Get Alerted Before Abviro LLC's Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start for free